Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 60.3% from a year ago

Net receivables stood at $106.99M at the end of Q3 FY2026, up 60.3% from a year earlier and up 4.8% from the prior quarter.

Context

  • Net receivables amounted to 10.8% of total assets at the end of Q3 FY2026, up 3.4 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +60.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$106.99M+4.8% QoQ
Last fiscal yearDec 2025
$82.45M+18.9% YoY
Year agoSep 2025
$66.76M+60.3% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.3%——
1 year+18.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
82.45M USD
Year-over-year change
+18.9%

Net Receivables vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +60.3% is the highest of 9, against a peer median of +2.2%.
  • Net receivables amounts to 10.8% of total assets for IOVA, versus a peer median of 1.0%.
IOVA Competitors
Net Receivables for IOVA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$1.28B USD+28.3%-41.4%10.2%
BNTXBioNTech SEJun 2026€245.1M EUR-83.1%-48.4%1.2%
LEGNLegend Biotech CorporationSep 2026$218.9M USD+8.1%+77.8%13.0%
IOVAIovance Biotherapeutics, Inc.Sep 2026$106.99M USD+60.3%—10.8%
IMCRImmunocore Holdings plcMar 2026$81.07M USD+28.5%+9.0%7.6%
IBRXImmunityBio, Inc.Sep 2026$53.6M USD+59.0%+182.5%8.8%
REPLReplimune Group, Inc.Dec 2025$2.96M USD-3.6%+6.8%0.9%
FATEFate Therapeutics, Inc.Mar 2026$704K USD-70.7%-71.2%0.2%
IMNMImmunome, Inc.Sep 2026$0 USD——0.0%
STTKShattuck Labs, Inc.Mar 2026$0 USD——0.0%
ALXOALX Oncology Holdings Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding IOVA) —+2.2%+6.8%1.0%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents78.23M231.73M114.89M115.69M163.08M
Short-term Investments426.18M240.11M164.98M208.09M133.9M
Net Receivables00151K69.34M82.45M
Inventory0010.37M51.52M51.68M
Other Current Assets07.27M17.46M12.38M11.58M
Total Current Assets507.96M479.12M307.85M457.02M442.69M
Property, Plant & Equipment (Net)169.92M178.25M176.55M164.28M177.01M
Goodwill00000
Intangible Assets00229.26M282.4M279.32M
Long-term Investments91.59M066.43M00
Tax Assets00000
Other Non-current Assets7.87M6.62M270K6.73M14.15M
Total Non-current Assets269.38M184.87M472.5M453.41M470.48M
Total Assets777.33M663.98M780.35M910.43M913.17M
Account Payables27.38M26.6M33.12M27.51M22.16M
Short-term Debt00004.04M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities0034.59M50.03M112.16M
Total Current Liabilities89.2M91.49M110.31M122.34M138.36M
Long-term Debt1M1M1M1M0
Deferred Tax Liabilities0017.35M32.32M31.83M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities66.47M72.86M85.43M77.68M76.23M
Total Liabilities155.67M164.34M195.74M200.02M214.59M
Common Stock7K8K11K13K17K
Retained Earnings(1.17B)(1.57B)(2.01B)(2.38B)(2.78B)
Accumulated OCI(601K)(902K)2.53M(1.05M)16.44M
Other Stockholders Equity00000
Minority Interest00000
Total Equity621.66M499.64M584.61M710.41M698.58M
Total Debt71.53M85.45M75.86M58.26M48.44M
Net Debt(6.7M)(146.29M)(39.03M)(57.43M)(114.63M)

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.